CAR-T therapy takes on tough lymphoma in Head-to-Head trial

NCT ID NCT05888493

Ongoing Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a personalized cell therapy called tisagenlecleucel (CAR-T) works better than standard treatments for adults with follicular lymphoma that has come back or stopped responding. About 109 participants will receive either the CAR-T infusion or standard options like lenalidomide plus rituximab or R-CHOP chemotherapy. The main goal is to see how long people live without their cancer getting worse.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

tisagenlecleucel (a CAR-T cell therapy made from the patient's own immune cells)

What this could lead to

If successful, this could offer a more effective treatment option for people with follicular lymphoma that has returned or not responded to prior therapies.

What could go wrong

This is an early-stage comparison, and CAR-T therapy can cause serious side effects like cytokine release syndrome. The trial is relatively small (109 participants), so results may not apply to everyone.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

follicular lymphoma Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FOLLICULAR LYMPHOMA (FL)

Contacts and locations

Show contact details

Locations

Novartis Investigative Site

Camperdown, New South Wales, 2050, Australia
Novartis Investigative Site

Clayton, Victoria, 3168, Australia
Novartis Investigative Site

Melbourne, Victoria, 3004, Australia
Novartis Investigative Site

Nedlands, Western Australia, 6009, Australia
Novartis Investigative Site

Salzburg, 5020, Austria
Novartis Investigative Site

Montreal, Quebec, H1T 2M4, Canada
Novartis Investigative Site

Ostrava, Poruba, 708 52, Czechia
Novartis Investigative Site

Budapest, H-1097, Hungary
Novartis Investigative Site

Poznan, Greater Poland Voivodeship, 60-355, Poland
Novartis Investigative Site

Gliwice, Silesian Voivodeship, 44-101, Poland
Novartis Investigative Site

Gdansk, 80-952, Poland
Novartis Investigative Site

Lodz, 93-513, Poland
Novartis Investigative Site

Singapore, 119074, Singapore
Novartis Investigative Site

Bratislava, 83310, Slovakia
Novartis Investigative Site

Seoul, 03080, South Korea
Novartis Investigative Site

Seoul, 03722, South Korea
Novartis Investigative Site

Seoul, 05505, South Korea
Novartis Investigative Site

Seoul, 06351, South Korea
Novartis Investigative Site

Seoul, 06591, South Korea
Novartis Investigative Site

Santiago Compostela, A Coruna, 15706, Spain
Novartis Investigative Site

L'Hospitalet de Llobregat, Barcelona, 08907, Spain
Novartis Investigative Site

Santander, Cantabria, 39008, Spain
Novartis Investigative Site

El Palmar, Murcia, 30120, Spain
Novartis Investigative Site

Barcelona, 08035, Spain
Novartis Investigative Site

Córdoba, 14004, Spain
Novartis Investigative Site

Madrid, 28034, Spain
Novartis Investigative Site

Salamanca, 37007, Spain
Novartis Investigative Site

Kaohsiung City, 83301, Taiwan
Novartis Investigative Site

Taichung, 407219, Taiwan
Novartis Investigative Site

Taipei, 10002, Taiwan